VectivBio, a clinical-stage biopharmaceutical company, agreed to acquire Comet Therapeutics, a privately held company that has been developing drugs to address previously untreatable inherited metabolic diseases. Financial terms were not disclosed. "The acquisition of the CoMET platform is in line with our core mission of developing disease-modifying treatments for rare severe diseases. The platform’s potential to deliver a pipeline of medicines that target the fundamental molecular pathophysiology of IMDs by unlocking previously inaccessible pathways, would provide us with the opportunity to transform the lives of these patients. We are eager to begin work on our new programs and look forward to progressing our first candidate towards the clinic," Luca Santarelli, VectivBio Founder and CEO.